People in the United States who seek treatment for obesity may soon have improved access to a reversible endoscopic intervention that can be performed in outpatient clinics—endoscopic sleeve gastroplasty, or ESG. The procedure triggers more weight loss and more durable weight loss than lifestyle changes, but is less invasive than surgery.
In July, the FDA cleared for marketing the first devices indicated for ESG and endoscopic bariatric revision: the Apollo ESG, Apollo